Zenagamtide once a week for type 2 diabetes not controlled by diet and exercise
Tests zenagamtide against placebo in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Key facts
- Where
- Boston, Fountain Valley, Hollywood, Houston, Los Angeles, Miami, Orlando, San Antonio, Spring Valley, Washington, Weston, and Wilmington, United StatesSee the 12 sites
- Phase
- Phase 3
Where in United States
- Brigham & Women's HospitalBoston, United StatesContact: Novo NordiskNo longer taking part
- Ark Clinical ResearchFountain Valley, United StatesContact: Novo NordiskNo longer taking part
- Encore Medical Research LLCHollywood, United StatesContact: Novo NordiskNo longer taking part
- Southwest Clinical TrialsHouston, United StatesContact: Novo NordiskNo longer taking part
- Los Angeles Institute for Metabolic ResearchLos Angeles, United StatesContact: Novo NordiskNo longer taking part
- My Preferred ResearchMiami, United StatesContact: Novo NordiskNo longer taking part
- Florida Institute for Clinical ResearchOrlando, United StatesContact: Novo NordiskNo longer taking part
- Pinnacle Clinical ResearchSan Antonio, United StatesContact: Novo NordiskNo longer taking part
- Encompass Clinical Research_Spring ValleySpring Valley, United StatesContact: Novo NordiskNo longer taking part
- Preferred Primary Care Physicians - WashingtonWashington, United StatesContact: Novo NordiskNo longer taking part
- Encore Medical Research of WestonWeston, United StatesContact: Novo NordiskNo longer taking part
- AccellacareWilmington, United StatesContact: Novo NordiskNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07931495EU 2026-525470-18-00
- Record updated
- 12 November 2026
- Original description
This study is being done to look at how well zenagamtide lowers blood sugar levels and body weight in people with type 2 diabetes when compared to placebo. Participants will either get zenagamtide, the treatment being tested or placebo, a treatment that has no active medicine in it. Which treatment participants get is decided by chance. Zenagamtide is a new medicine that doctors cannot prescribe yet, but it has been tested in humans before.Read full original descriptionShow less
Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Diet and Exercise
This study is being done to look at how well zenagamtide lowers blood sugar levels and body weight in people with type 2 diabetes when compared to placebo. Participants will either get zenagamtide, the treatment being tested or placebo, a treatment that has no active medicine in it. Which treatment participants get is decided by chance. Zenagamtide is a new medicine that doctors cannot prescribe yet, but it has been tested in humans before.
Inclusion: Male or female (sex assigned at birth, inclusive of all gender identities); Age 18 years or above at the time of signing the informed consent; Diagnosed with type 2 diabetes (T2D) greater than or equal to (≥) 30 days before screening; Treatment naïve to any glucose-lowering medication(s).
Exclusion: Current treatment or history of treatment with any medication for the indication of diabetes, or treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues for any indication. However, previous insulin treatment during Gestational Diabetes Mellitus is allowed; Treatment with any medication for the indication of obesity before screening; Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or are expected to require treatment within 180 days after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination; Myocardial infarction, stroke, transient ischaemic attack or hospitalisation for unstable angina pectoris within 60 days before screening; Chronic heart failure classified as being in New York Heart Association (NYHA) Class IV at screening; Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method; Planned coronary, carotid or peripheral artery revascularisation.